FibroBiologics Change In Cash from 2010 to 2026
| FBLG Stock | 0.25 0.01 3.85% |
Change In Cash | First Reported 2010-12-31 | Previous Quarter 5.5 M | Current Value 3.8 M | Quarterly Volatility 2.2 M |
Check FibroBiologics Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among FibroBiologics Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 454.6 K, Selling General Administrative of 11.1 M or Other Operating Expenses of 16.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.72. FibroBiologics financial statements analysis is a perfect complement when working with FibroBiologics Common Valuation or Volatility modules.
FibroBiologics | Change In Cash | Build AI portfolio with FibroBiologics Stock |
The Change In Cash trend for FibroBiologics Common Stock offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether FibroBiologics Common is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest FibroBiologics Common's Change In Cash Growth Pattern
Below is the plot of the Change In Cash of FibroBiologics Common Stock over the last few years. It is FibroBiologics Common's Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in FibroBiologics Common's overall financial position and show how it may be relating to other accounts over time.
| Change In Cash | 10 Years Trend |
|
Change In Cash |
| Timeline |
FibroBiologics Change In Cash Regression Statistics
| Arithmetic Mean | 1,638,422 | |
| Geometric Mean | 809,010 | |
| Coefficient Of Variation | 133.17 | |
| Mean Deviation | 1,738,478 | |
| Median | 407,000 | |
| Standard Deviation | 2,181,883 | |
| Sample Variance | 4.8T | |
| Range | 6.5M | |
| R-Value | 0.73 | |
| Mean Square Error | 2.4T | |
| R-Squared | 0.53 | |
| Significance | 0.0009 | |
| Slope | 314,282 | |
| Total Sum of Squares | 76.2T |
FibroBiologics Change In Cash History
About FibroBiologics Common Financial Statements
FibroBiologics Common stakeholders use historical fundamental indicators, such as FibroBiologics Common's Change In Cash, to determine how well the company is positioned to perform in the future. Although FibroBiologics Common investors may analyze each financial statement separately, they are all interrelated. For example, changes in FibroBiologics Common's assets and liabilities are reflected in the revenues and expenses on FibroBiologics Common's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in FibroBiologics Common Stock. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Change In Cash | 5.5 M | 3.8 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of FibroBiologics Common Correlation against competitors. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Can Biotechnology industry sustain growth momentum? Does FibroBiologics have expansion opportunities? Factors like these will boost the valuation of FibroBiologics Common. Market participants price FibroBiologics higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating FibroBiologics Common demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, FibroBiologics Common's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.